ticlopidine has been researched along with No-Reflow Phenomenon in 6 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
No-Reflow Phenomenon: Markedly reduced or absent REPERFUSION in an infarct zone following the removal of an obstruction or constriction of an artery.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our study showed that clopidogrel resistance may be one of the responsible mechanisms for the no-reflow phenomenon." | 7.78 | Impact of clopidogrel resistance on ST-segment resolution and no-reflow in acute myocardial infarction with ST-elevation patients treated with a primary percutaneous coronary intervention. ( Aksu, H; Bozbeyoglu, E; Nurkalem, Z; Satilmis, S; Yildirimturk, O, 2012) |
| "The aim of the present study was to compare 600- and 300-mg clopidogrel loading doses in patients with ST-segment elevation myocardial infarctions who underwent primary percutaneous coronary intervention (PCI)." | 7.76 | Comparison of 600 versus 300-mg Clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty. ( Barbato, E; Bartunek, J; De Bruyne, B; Heyndrickx, GR; Mangiacapra, F; Muller, O; Ntalianis, A; Trana, C; Vanderheyden, M; Wijns, W, 2010) |
| "Our study showed that clopidogrel resistance may be one of the responsible mechanisms for the no-reflow phenomenon." | 3.78 | Impact of clopidogrel resistance on ST-segment resolution and no-reflow in acute myocardial infarction with ST-elevation patients treated with a primary percutaneous coronary intervention. ( Aksu, H; Bozbeyoglu, E; Nurkalem, Z; Satilmis, S; Yildirimturk, O, 2012) |
| "The aim of the present study was to compare 600- and 300-mg clopidogrel loading doses in patients with ST-segment elevation myocardial infarctions who underwent primary percutaneous coronary intervention (PCI)." | 3.76 | Comparison of 600 versus 300-mg Clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty. ( Barbato, E; Bartunek, J; De Bruyne, B; Heyndrickx, GR; Mangiacapra, F; Muller, O; Ntalianis, A; Trana, C; Vanderheyden, M; Wijns, W, 2010) |
| "Patients with STEMI undergoing PPCI within 12hours of symptoms onset were included prospectively." | 1.46 | Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. ( Aitmokhtar, O; Azaza, A; Azzouz, A; Benamara, S; Benathmane, T; Benkhedda, S; Bonello, L; Bouzid, A; Hamza, O; Harbi, F; Kara, M; Monsuez, JJ; Paganelli, F; Saidane, M; Seddiki, S; Sik, A, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aitmokhtar, O | 1 |
| Paganelli, F | 1 |
| Benamara, S | 1 |
| Azaza, A | 1 |
| Bonello, L | 1 |
| Hamza, O | 1 |
| Seddiki, S | 1 |
| Benathmane, T | 1 |
| Saidane, M | 1 |
| Bouzid, A | 1 |
| Kara, M | 1 |
| Sik, A | 1 |
| Azzouz, A | 1 |
| Harbi, F | 1 |
| Monsuez, JJ | 1 |
| Benkhedda, S | 1 |
| Kuliczkowski, W | 1 |
| Gasior, M | 1 |
| Pres, D | 1 |
| Kaczmarski, J | 1 |
| Laszowska, A | 1 |
| Szewczyk, M | 1 |
| Hawranek, M | 1 |
| Tajstra, M | 1 |
| Zeglen, S | 1 |
| Polonski, L | 1 |
| Serebruany, VL | 1 |
| Ren, F | 1 |
| Mu, N | 1 |
| Zhang, X | 1 |
| Tan, J | 1 |
| Li, L | 1 |
| Zhang, C | 1 |
| Dong, M | 1 |
| Mangiacapra, F | 1 |
| Muller, O | 1 |
| Ntalianis, A | 1 |
| Trana, C | 1 |
| Heyndrickx, GR | 1 |
| Bartunek, J | 1 |
| Vanderheyden, M | 1 |
| Wijns, W | 1 |
| De Bruyne, B | 1 |
| Barbato, E | 1 |
| Bozbeyoglu, E | 1 |
| Satilmis, S | 1 |
| Aksu, H | 1 |
| Yildirimturk, O | 1 |
| Nurkalem, Z | 1 |
| Riml, S | 1 |
| Wallner, H | 1 |
| Kompatscher, P | 1 |
6 other studies available for ticlopidine and No-Reflow Phenomenon
| Article | Year |
|---|---|
Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Topics: Aged; Area Under Curve; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Ang | 2017 |
Aspirin 'resistance': impact on no-reflow, platelet and inflammatory biomarkers in diabetics after ST-segment elevation myocardial infarction.
Topics: Aged; Aspirin; Biomarkers; Clopidogrel; Diabetes Complications; Drug Resistance; Female; Humans; Inf | 2015 |
Increased Platelet-leukocyte Aggregates Are Associated With Myocardial No-reflow in Patients With ST Elevation Myocardial Infarction.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary Thrombos | 2016 |
Comparison of 600 versus 300-mg Clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Clopidogrel; Combined Modality Therap | 2010 |
Impact of clopidogrel resistance on ST-segment resolution and no-reflow in acute myocardial infarction with ST-elevation patients treated with a primary percutaneous coronary intervention.
Topics: Clopidogrel; Coronary Angiography; Coronary Circulation; Drug Resistance; Electrocardiography; Femal | 2012 |
Friend or foe? Discussion about dual platelet inhibition as a salvage procedure from imminent flap failure.
Topics: Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Mamma | 2013 |